<- Go Home
Instil Bio, Inc.
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Market Cap
$150.2M
Volume
77.0K
Cash and Equivalents
$6.7M
EBITDA
-$56.9M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
N/A
Profit Margin
N/A
52 Week High
$92.00
52 Week Low
$9.62
Dividend
N/A
Price / Book Value
0.85
Price / Earnings
-1.99
Price / Tangible Book Value
0.85
Enterprise Value
$114.4M
Enterprise Value / EBITDA
-2.11
Operating Income
-$60.8M
Return on Equity
36.63%
Return on Assets
-12.40
Cash and Short Term Investments
$121.1M
Debt
$85.3M
Equity
$176.3M
Revenue
N/A
Unlevered FCF
-$19.3M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium